Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Benefits of Peanut Desensitization May Not Last

Key clinical point: Discontinuing or reducing peanut OIT to 300 mg daily increased the potential of regaining an allergic reaction.

Major finding: At week 156, after a year of avoiding peanut, 37% of patients reduced to 300 mg of peanut OIT passed an allergy challenge, compared with 13% of those who totally discontinued OIT and 4% of a placebo group.

Study details: The data come from a randomized, phase 2 study of 120 individuals aged 7-55 years with peanut allergies.

Disclosures: The National Institutes of Health supported the study. The researchers had no financial conflicts to disclose.

Citation:

Chinthrajah RS et al. Lancet. 2019 Sep 12. doi: 10.1016/S0140-6736(19)31793-3.